CGAS-STING Signaling Pathway in Lung Cancer: Regulation on Antitumor Immunity and Application in Immunotherapy

Overview

Journal Chin Med J Pulm Crit Care Med

Date 2025 Jan 21

PMID 39834588

Authors

Jing Wu

Yingyao Chen

Mengqing Xie

Xin Yu

Chunxia Su

Affiliations

Soon will be listed here.

Abstract

The innate immune system has a primary role in defending against external threats, encompassing viruses, bacteria, and fungi, thereby playing a pivotal role in establishing robust protection. Recent investigations have shed light on its importance in the progression of tumors, with a particular emphasis on lung cancer. Among the various signaling pathways implicated in this intricate process, the cGAS-STING pathway emerges as a significant participant. Cyclic GMP-AMP synthase (cGAS) discerns free DNA and activates the stimulator of interferon genes (STING), subsequently culminating in the secretion of cytokines and exerting inhibitory effects on tumor development. Consequently, researchers are increasingly interested in creating anticancer drugs that specifically target the cGAS-STING pathway, offering promising avenues for novel therapeutic interventions. The objective of this review is to present a comprehensive overview of the ongoing research on the cGAS-STING signaling pathway within the realm of lung cancer. The primary emphasis is on understanding its involvement in lung cancer development and assessing its viability as a target for innovative therapeutic options.

References

Mohamed E, Sierra R, Trillo-Tinoco J, Cao Y, Innamarato P, Payne K . The Unfolded Protein Response Mediator PERK Governs Myeloid Cell-Driven Immunosuppression in Tumors through Inhibition of STING Signaling. Immunity. 2020; 52(4):668-682.e7. PMC: 7207019. DOI: 10.1016/j.immuni.2020.03.004. View

de Palma M, Biziato D, Petrova T . Microenvironmental regulation of tumour angiogenesis. Nat Rev Cancer. 2017; 17(8):457-474. DOI: 10.1038/nrc.2017.51. View

Zhou M, Fan J, Li Z, Li P, Sun Y, Yang Y . Prognostic impact of tumor mutation burden and the mutation in KIAA1211 in small cell lung cancer. Respir Res. 2019; 20(1):248. PMC: 6836503. DOI: 10.1186/s12931-019-1205-9. View

Galluzzi L, Vanpouille-Box C, Bakhoum S, Demaria S . SnapShot: CGAS-STING Signaling. Cell. 2018; 173(1):276-276.e1. DOI: 10.1016/j.cell.2018.03.015. View

Chiriva-Internati M, Liu Y, Weidanz J, Grizzi F, You H, Zhou W . Testing recombinant adeno-associated virus-gene loading of dendritic cells for generating potent cytotoxic T lymphocytes against a prototype self-antigen, multiple myeloma HM1.24. Blood. 2003; 102(9):3100-7. DOI: 10.1182/blood-2002-11-3580. View

Demaria O, de Gassart A, Coso S, Gestermann N, Di Domizio J, Flatz L . STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity. Proc Natl Acad Sci U S A. 2015; 112(50):15408-13. PMC: 4687570. DOI: 10.1073/pnas.1512832112. View

Ishikawa H, Barber G . STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature. 2008; 455(7213):674-8. PMC: 2804933. DOI: 10.1038/nature07317. View

Yang Y, An Y, Ren M, Wang H, Bai J, Du W . The mechanisms of action of mitochondrial targeting agents in cancer: inhibiting oxidative phosphorylation and inducing apoptosis. Front Pharmacol. 2023; 14:1243613. PMC: 10635426. DOI: 10.3389/fphar.2023.1243613. View

Sharma P, Hu-Lieskovan S, Wargo J, Ribas A . Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell. 2017; 168(4):707-723. PMC: 5391692. DOI: 10.1016/j.cell.2017.01.017. View

10.

Fu J, Kanne D, Leong M, Glickman L, McWhirter S, Lemmens E . STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade. Sci Transl Med. 2015; 7(283):283ra52. PMC: 4504692. DOI: 10.1126/scitranslmed.aaa4306. View

11.

Corrales L, Glickman L, McWhirter S, Kanne D, Sivick K, Katibah G . Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. Cell Rep. 2015; 11(7):1018-30. PMC: 4440852. DOI: 10.1016/j.celrep.2015.04.031. View

12.

Li X, Wenes M, Romero P, Huang S, Fendt S, Ho P . Navigating metabolic pathways to enhance antitumour immunity and immunotherapy. Nat Rev Clin Oncol. 2019; 16(7):425-441. DOI: 10.1038/s41571-019-0203-7. View

13.

Cannan W, Pederson D . Mechanisms and Consequences of Double-Strand DNA Break Formation in Chromatin. J Cell Physiol. 2015; 231(1):3-14. PMC: 4994891. DOI: 10.1002/jcp.25048. View

14.

Byers L, Wang J, Nilsson M, Fujimoto J, Saintigny P, Yordy J . Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov. 2012; 2(9):798-811. PMC: 3567922. DOI: 10.1158/2159-8290.CD-12-0112. View

15.

McKeage M, Jameson M . Comparative outcomes of squamous and non-squamous non-small cell lung cancer (NSCLC) patients in phase II studies of ASA404 (DMXAA) - retrospective analysis of pooled data. J Thorac Dis. 2012; 2(4):199-204. PMC: 3256477. DOI: 10.3978/j.issn.2072-1439.2010.02.04.1. View

16.

McKeage M, Reck M, Jameson M, Rosenthal M, Gibbs D, Mainwaring P . Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Lung Cancer. 2009; 65(2):192-7. DOI: 10.1016/j.lungcan.2009.03.027. View

17.

Depil S, Duchateau P, Grupp S, Mufti G, Poirot L . 'Off-the-shelf' allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020; 19(3):185-199. DOI: 10.1038/s41573-019-0051-2. View

18.

Cavlar T, Deimling T, Ablasser A, Hopfner K, Hornung V . Species-specific detection of the antiviral small-molecule compound CMA by STING. EMBO J. 2013; 32(10):1440-50. PMC: 3655471. DOI: 10.1038/emboj.2013.86. View

19.

Marcus A, Mao A, Lensink-Vasan M, Wang L, Vance R, Raulet D . Tumor-Derived cGAMP Triggers a STING-Mediated Interferon Response in Non-tumor Cells to Activate the NK Cell Response. Immunity. 2018; 49(4):754-763.e4. PMC: 6488306. DOI: 10.1016/j.immuni.2018.09.016. View

20.

Schreiber G, Piehler J . The molecular basis for functional plasticity in type I interferon signaling. Trends Immunol. 2015; 36(3):139-49. DOI: 10.1016/j.it.2015.01.002. View